JB Pharma Q4 PAT Down 30% YoY

JB Pharma reported Q4 FY26 revenue of Rs 904 crore, down 5% YoY, with PAT declining 30% to Rs 101 crore.
The quarter was impacted by one-off operational reset costs from post-acquisition integration and alignment with parent company practices.
Full-year FY26 revenue grew 6% to Rs 4,148 crore with PAT up 8% to Rs 709 crore, while gross and EBITDA margins expanded.
Management expects business performance to progressively improve from Q1 FY27 as integration impacts are temporary.